Kindred Biosciences is a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets. Co.'s portfolio includes: Mirataz®, which is its transdermal drug for the management of weight loss in cats; and Zimeta™, which is for the control of pyrexia in horses. Co.'s product candidates include: KIND-016, a fully caninized monoclonal antibody targeting interleukin-31 for the treatment of atopic dermatitis in dogs; KIND-032, a fully caninized monoclonal antibody targeting interleukin-4 (IL-4) receptor for the treatment of atopic dermatitis in dogs; and KIND-025, a canine fusion protein targeting IL-4 and IL-13, for the treatment of atopic dermatitis in dogs. The KIN average annual return 10 years is shown above.
The Average Annual Return on the KIN average annual return 10 years page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether KIN average annual return 10 years or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the KIN average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Video: Don't Forget Dividends in Average Annual Return!
